EUVIMEDEUVIMED entdecken
Open Access

A Plasma miR-193b-365 Signature Combined With Age and Glycemic Status Predicts Response to Lactococcus lactis –Based Antigen-Specific Immunotherapy in New-Onset Type 1 Diabetes

Gabriele Sassi iD, Giada Licata, Giuliana Ventriglia, Amber Wouters, Pierre Lemaitre, Ruth Seurinck, Alessia Mori, Giuseppina Emanuela Grieco, Samal Bissenova, Darcy Ellis, Silvia Caluwaerts, Pieter Rottiers und 5 weitere

Diabetes · 2023

DOI: 10.2337/db22-0852 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, 2023. Verfasst von Gabriele Sassi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Experimental Endocrinology, Chrometa, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Lactococcus lactis, MicroRNAs. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: KU Leuven, Research Foundation Flanders, Hippo & Friends type 1 diabetes and Carpe Diem.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunomodulation combined with antigen therapy holds great promise to arrest autoimmune type 1 diabetes, but clinical translation is hampered by a lack of prognostic biomarkers. Low-dose anti-CD3 plus Lactococcus lactis bacteria secreting proinsulin and IL-10 reversed new-onset disease in nonobese diabetic (NOD) mice, yet some mice were resistant to the therapy. Using miRNA profiling, six miRNAs (i.e., miR-34a-5p, miR-125a-3p, miR-193b-3p, miR-328, miR-365–3p, and miR-671–3p) were identified as differentially expressed in plasma of responder versus nonresponder mice before study entry. After validation and stratification in an independent cohort, plasma miR-193b-3p and miR-365–3p, combined with age and glycemic status at study entry, had the best power to predict, with high sensitivity and specificity, poor response to the therapy. These miRNAs were highly abundant in pancreas-infiltrating neutrophils and basophils with a proinflammatory and activated phenotype. Here, a set of miRNAs and disease-associated parameters are presented as a predictive signature for the L. lactis–based immunotherapy outcome in new-onset type 1 diabetes, hence allowing targeted recruitment of trial participants and accelerated trial execution. Article Highlights Low-dose anti-CD3 combined with oral gavage of genetically modified Lactococcus lactis bacteria secreting human proinsulin and IL-10 holds great promise to arrest autoimmune type 1 diabetes, but the absence of biomarkers predicting therapeutic success hampers clinical translation. A set of cell-free circulation miRNAs together with age and glycemia at baseline predicts a poor response after L. lactis–based immunotherapy in nonobese mice with new-onset diabetes. Pancreas-infiltrating neutrophils and basophils are identified as potential cellular sources of discovered miRNAs. The prognostic signature could guide targeted recruitment of patients with newly diagnosed type 1 diabetes in clinical trials with the L. lactis–based immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Lactococcus lactisMicroRNAsHumansAnimalsMiceInterleukin-10ProinsulinGene Expression ProfilingBiomarkersMice, Inbred NODImmunotherapy

Substanzen

Interleukin-10ProinsulinMicroRNAsBiomarkersMIRN365 microRNA, human

Autor:innen und Institutionen

  • Clinical and Experimental Endocrinology, Chrometa, KU Leuven, Leuven, Belgium.
  • Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
  • Fondazione Umberto Di Mario ONLUS, Toscana Life Science, Siena, Italy.
  • Data Mining and Modelling for Biomedicine, VIB Center for Inflammation Research, Ghent, Belgium.
  • Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium.
  • Tuscany Centre for Precision Medicine, Siena, Italy.

ORCID-Profile: Gabriele Sassi, Chantal Mathieu, Francesco Dotta, Guido Sebastiani

Förderung

  • KU Leuven
  • Research Foundation Flanders
  • Hippo & Friends type 1 diabetes and Carpe Diem

Zitieren

APA

Sassi, G., Licata, G., Ventriglia, G., Wouters, A., Lemaitre, P., Seurinck, R., Mori, A., Grieco, G. E., Bissenova, S., Ellis, D., Caluwaerts, S., Rottiers, P., Vandamme, N., Mathieu, C., Dotta, F., Gysemans, C., & Sebastiani, G. (2023). A Plasma miR-193b-365 Signature Combined With Age and Glycemic Status Predicts Response to Lactococcus lactis –Based Antigen-Specific Immunotherapy in New-Onset Type 1 Diabetes. Diabetes. https://doi.org/10.2337/db22-0852

Vancouver

Sassi G, Licata G, Ventriglia G, Wouters A, Lemaitre P, Seurinck R, et al. A Plasma miR-193b-365 Signature Combined With Age and Glycemic Status Predicts Response to Lactococcus lactis –Based Antigen-Specific Immunotherapy in New-Onset Type 1 Diabetes. Diabetes. 2023. doi:10.2337/db22-0852

BibTeX
@article{Sassi2023,
  author = {Sassi, Gabriele and Licata, Giada and Ventriglia, Giuliana and Wouters, Amber and Lemaitre, Pierre and Seurinck, Ruth and Mori, Alessia and Grieco, Giuseppina Emanuela and Bissenova, Samal and Ellis, Darcy and Caluwaerts, Silvia and Rottiers, Pieter and Vandamme, Niels and Mathieu, Chantal and Dotta, Francesco and Gysemans, Conny and Sebastiani, Guido},
  title = {A Plasma miR-193b-365 Signature Combined With Age and Glycemic Status Predicts Response to Lactococcus lactis –Based Antigen-Specific Immunotherapy in New-Onset Type 1 Diabetes},
  journal = {Diabetes},
  year = {2023},
  doi = {10.2337/db22-0852}
}
Kostenlos starten →